Folitrax 15mg Injection (Methotrexate)

Description

Folitrax 15mg Injection (Methotrexate) — Complete Clinical and Patient Information Guide

Product Overview

Folitrax 15mg Injection (Methotrexate) contains Methotrexate Sodium 15mg injection as its active pharmaceutical ingredient, belonging to the folate antimetabolite — anti-inflammatory immunomodulator (low dose) / cytotoxic agent (high dose). It is clinically indicated for rheumatoid arthritis, psoriasis (moderate-to-severe plaque psoriasis), psoriatic arthritis, juvenile idiopathic arthritis, dermatomyositis — at low weekly doses; acute lymphoblastic leukaemia, osteosarcoma, non-Hodgkin lymphoma, breast cancer, gestational trophoblastic disease — at chemotherapy doses. This guide is prepared in accordance with YMYL (Your Money Your Life) content standards, drawing on regulatory prescribing information, peer-reviewed pharmacological literature, and established clinical guidelines. Cancer and specialty medications require specialist initiation and monitoring — this information is educational and does not replace professional medical guidance.

Folitrax (Ipca Laboratories) is India’s most widely prescribed low-dose weekly MTX formulation for RA and psoriasis, available across the full dose range (2.5mg-25mg). Sodium as an injectable formulation for parenteral delivery.

Mechanism of Action

Methotrexate (MTX) is a folate antimetabolite with dose-dependent mechanisms. At low doses (weekly anti-inflammatory dosing: 7.5–25mg/week for RA, psoriasis), the primary anti-inflammatory mechanism is inhibition of AICAR transformylase — an enzyme in the purine synthesis pathway downstream of dihydrofolate reductase (DHFR). This causes accumulation of AICAR (aminoimidazole carboxamide ribonucleotide) and subsequently adenosine — a potent endogenous immunosuppressant that inhibits T-cell activation, reduces TNF-alpha production, suppresses neutrophil function, and modulates NF-κB signalling. At high doses (chemotherapy: 500–12,000 mg/m² IV with leucovorin rescue), MTX’s primary mechanism is competitive inhibition of DHFR — the enzyme that regenerates tetrahydrofolate (THF) from dihydrofolate. DHFR inhibition depletes reduced folate pools required for thymidylate synthesis and purine biosynthesis, impeding DNA replication and RNA synthesis in rapidly dividing cells (cancer cells, bone marrow, GI epithelium). MTX also inhibits thymidylate synthase (TS) through polyglutamate metabolites (MTXPG), which are retained intracellularly, prolonging the drug’s effect beyond plasma half-life. The distinction between anti-inflammatory and cytotoxic MTX use is critical: low-dose weekly MTX for RA/psoriasis acts primarily through adenosine-mediated immunomodulation, while chemotherapy MTX acts through folate depletion and DNA synthesis inhibition.

Clinical Indications

Folitrax 15mg Injection (Methotrexate) is indicated for rheumatoid arthritis, psoriasis (moderate-to-severe plaque psoriasis), psoriatic arthritis, juvenile idiopathic arthritis, dermatomyositis — at low weekly doses; acute lymphoblastic leukaemia, osteosarcoma, non-Hodgkin lymphoma, breast cancer, gestational trophoblastic disease — at chemotherapy doses. Specialist confirmation of diagnosis, eligibility for treatment, and initiation of therapy are mandatory — self-diagnosis and self-treatment of these conditions can be dangerous and may delay or undermine appropriate clinical management.

Dosage and Administration

INJECTABLE: dose and frequency determined by specialist based on indication. Inject SC or IM. Injectable formulations provide more reliable absorption than oral at equivalent doses — preferred when GI side effects limit oral MTX or at higher doses. Folitrax injections are for subcutaneous, intramuscular, or intrathecal use under specialist direction only.

Contraindications

Hypersensitivity. Severe hepatic impairment or pre-existing liver fibrosis/cirrhosis. Severe renal impairment (MTX is renally excreted — accumulates in renal impairment, causing severe toxicity). Active infection (significant immunosuppression). Pregnancy (ABSOLUTE CONTRAINDICATION — MTX causes foetal death and severe teratogenicity; effective contraception mandatory for both males and females during therapy and for 6 months after stopping). Breastfeeding. Active alcoholism.

Drug Interactions

NSAIDs: increase MTX plasma levels by reducing renal tubular secretion — increased toxicity risk; monitor closely or use with caution at low anti-inflammatory doses (often co-prescribed under supervision). Proton pump inhibitors (particularly omeprazole): reduce MTX renal clearance — increased toxicity. Trimethoprim/co-trimoxazole: additive antifolate toxicity — AVOID. Penicillins: reduce MTX clearance — monitor. Ciclosporin: additive nephrotoxicity and hepatotoxicity. Live vaccines: contraindicated during MTX immunosuppression.

Adverse Effects

Myelosuppression (nadir 7–14 days). Mucositis, nausea, vomiting. Hepatotoxicity. Nephrotoxicity (at high doses — hydration essential). Neurotoxicity (intrathecal administration — arachnoiditis, leukoencephalopathy). Pulmonary toxicity.

Special Population Considerations

High-dose MTX requires leucovorin (folinic acid) rescue — administered 24 hours after MTX to prevent systemic folate depletion. Intensive hydration and urinary alkalinisation required. Serum MTX levels monitored to guide leucovorin rescue. Only administer in specialist oncology units with appropriate supportive care.

Storage

Store Folitrax 15mg Injection per manufacturer guidelines. Most oral tablets at room temperature (15–25°C) away from heat, light, and moisture. Injectable medications require refrigeration or specific temperature control — follow pharmacy instructions. Keep out of reach of children and dispose of expired medications through authorised pharmaceutical take-back services.

Frequently Asked Questions

Q: How should I store this medication?
A: Store at room temperature (15–25°C), away from direct sunlight, heat, and moisture. Keep in original packaging out of reach of children. Injectable oncology medications require specialised storage — follow manufacturer and pharmacy guidance. Do not use beyond the printed expiry date.

Q: What should I do if I miss a dose?
A: For most medications: take as soon as you remember unless it is nearly time for the next dose. Never double-dose. For oncology medications, missed doses should be discussed with your oncologist before taking. Do not stop cancer medications without oncologist guidance.

Q: What is leucovorin rescue and why is it needed?
A: Leucovorin (folinic acid) rescue is a specific antidote administered after high-dose methotrexate infusion. High-dose MTX depletes systemic folate required for normal cell function in all rapidly dividing tissues (bone marrow, GI mucosa). Leucovorin replenishes folate in normal cells, rescuing them from MTX toxicity, while cancer cells (which have reduced folate transport) receive less benefit. Leucovorin must be started at a precise time after MTX and continued until MTX levels fall below the toxic threshold — monitored by serum MTX levels.

Evidence Base, Regulatory Status, and Quality Standards

The active ingredient in Folitrax 15mg Injection has been evaluated in clinical trials and regulatory submissions reviewed by competent health authorities. Oncology and specialty medications are subject to stringent regulatory scrutiny given their risk-benefit profiles in serious conditions. Major oncology guidelines from ESMO, ASCO, NCCN, and relevant national bodies inform prescribing decisions. All medications should be obtained through licensed, regulated pharmacies with valid prescriptions from registered specialists to ensure receipt of authentic, quality-assured products. GMP compliance ensures consistent product quality, identity, strength, and purity.

Cancer and Specialty Medicine Clinical Context

Cancer represents the second leading cause of death globally, accounting for approximately 10 million deaths annually. Modern oncology has been transformed by targeted therapy — drugs designed around specific molecular alterations in cancer cells (BCR-ABL in CML, HER2 in breast cancer, EGFR/ALK in NSCLC, VEGFR in solid tumours) achieving outcomes unimaginable with conventional chemotherapy. The era of precision oncology requires molecular profiling of each patient’s tumour before prescribing targeted agents — EGFR testing for erlotinib/gefitinib, HER2 testing for trastuzumab, ALK testing for ceritinib, and BCR-ABL for imatinib.

Conventional chemotherapy agents (paclitaxel, carboplatin, cyclophosphamide, fluorouracil, epirubicin, oxaliplatin, irinotecan, gemcitabine, dacarbazine, cytarabine, etoposide) remain essential backbones of cancer treatment — often combined with targeted agents in multi-drug regimens. Their cytotoxic mechanisms targeting rapidly dividing cells inevitably affect normal bone marrow, GI mucosa, and hair follicles — explaining myelosuppression, mucositis, and alopecia as class-wide adverse effects that require supportive care.

Haematological malignancies — leukaemias, lymphomas, multiple myeloma — represent a distinct oncological domain where molecular-targeted drugs have achieved remarkable results: imatinib transformed CML from a uniformly fatal disease to one with near-normal life expectancy; rituximab dramatically improved lymphoma outcomes; and the IMiD class (thalidomide, lenalidomide, pomalidomide) has progressively extended myeloma survival.

Parasitic Disease and Tropical Medicine Context

Parasitic infections cause enormous global morbidity — lymphatic filariasis affects 120 million people causing disfiguring lymphoedema; onchocerciasis blinds millions in sub-Saharan Africa; intestinal helminths impair growth and cognition in hundreds of millions of children; scabies infects approximately 200 million people globally; and Giardia/Cryptosporidium cause millions of diarrhoeal episodes annually. Ivermectin, albendazole, mebendazole, and DEC are WHO Essential Medicines — available for low cost and capable of eliminating these diseases when deployed through mass drug administration programmes.

Evidence Base and Quality Standards

The active ingredients in this product range have been evaluated in landmark clinical trials forming the evidence base for modern oncology, infectious disease, and specialty medicine: IPASS (gefitinib in EGFR-mutant NSCLC), ALEX (alectinib in ALK+ NSCLC), BOLERO-2 (everolimus+exemestane), ATAC (anastrozole), COU-AA-301/302 (abiraterone), AFFIRM/PREVAIL (enzalutamide), INPULSIS (nintedanib), ASTRAL-1 to 4 (sofosbuvir/velpatasvir), and many others. GMP-compliant manufacturing ensures consistent pharmaceutical quality. Patients must obtain oncology and specialty medications from licensed pharmacies with valid prescriptions from registered specialists.

Patient Safety, Monitoring, and Adherence

Oncology and specialty pharmacotherapy requires active patient engagement for optimal outcomes. Adherence to oral cancer drugs is critical — missed doses of TKIs like imatinib, erlotinib, and enzalutamide directly reduce drug exposure and potentially allow tumour progression or drug resistance development. Studies in CML show that patients with <80% imatinib adherence have significantly worse molecular response rates and higher transformation risk. The same principle applies to endocrine therapy for breast cancer — patients discontinuing anastrozole or tamoxifen early have substantially higher recurrence rates. Adherence support, side effect management, and patient education are as important as drug selection.

Monitoring requirements for specialty medications are stringent and non-negotiable. FBC monitoring during chemotherapy and methotrexate therapy prevents life-threatening myelosuppression complications. LFT monitoring during TKI and anthracycline therapy detects hepatotoxicity before it becomes severe. Cardiac monitoring during trastuzumab and anthracycline therapy prevents irreversible cardiomyopathy. Molecular monitoring (BCR-ABL PCR, HCV RNA, HBV DNA) determines treatment response and guides duration decisions.

All patients on oncology and specialty medications benefit from structured support: specialist oncology nurse coordination, patient support groups, pharmacist medication counselling, and regular specialist review. Complex medication regimens should be clearly written, explained verbally, and reviewed at each clinical encounter to identify any confusion, interactions, or emerging side effects requiring management.

Responsible Use and Safe Disposal

Oncology medications — particularly oral cytotoxic agents (cyclophosphamide, capecitabine, temozolomide, methotrexate) — are hazardous drugs requiring careful handling. Pregnant women and those planning pregnancy should not handle broken or crushed oral cytotoxic tablets. Unused or expired medications must be returned to a licensed pharmacy for safe hazardous pharmaceutical disposal — never disposed of in household waste or toilet.

Multi-Disciplinary Oncology Care

Modern cancer management requires multi-disciplinary team (MDT) decision-making — integrating oncologists, surgeons, radiologists, pathologists, specialist nurses, and pharmacists to develop individualised treatment plans. Pharmacological therapy (chemotherapy, targeted agents, endocrine therapy, immunotherapy) is one component of comprehensive cancer care alongside surgery (with curative intent for localised disease), radiotherapy (definitive, adjuvant, or palliative), and supportive/palliative care. Clinical trials offer access to novel therapies and the opportunity to advance cancer treatment knowledge — eligible patients should be offered trial participation where available.

Oncology pharmacy practice has become a specialised discipline — oncology pharmacists review complex multi-drug regimens for interactions and dosing errors, prepare hazardous IV chemotherapy safely, counsel patients on managing side effects of oral cancer drugs, and monitor for drug-induced toxicities. The safe use of oncology medications depends on this specialised expertise at every step from prescription to administration.

Palliative and supportive care integration is equally important — managing cancer symptoms (pain, nausea, fatigue, dyspnoea) and treatment side effects (chemotherapy-induced nausea, peripheral neuropathy, immunosuppression, mucositis) maintains quality of life throughout the cancer journey. Early palliative care integration (not just end-of-life care) improves patient outcomes and quality of life even in patients receiving active curative therapy.

Drug Supply and Authentic Procurement

For oncology and specialty medicines, procurement from authenticated, licensed sources is critically important. Counterfeit cancer medications are a documented global public health problem — they range from diluted products (containing less active ingredient than labelled, providing inadequate treatment) to products containing no active ingredient, to products with contaminated or substituted ingredients causing direct harm. Always obtain cancer medications from licensed, regulated pharmacies with valid prescriptions. Indian regulatory authority (CDSCO) oversight and manufacturer GMP compliance provide assurance of product quality for domestically produced cancer medicines.

Important Medical Disclaimer

This product information guide is provided for general educational purposes only, prepared in accordance with YMYL (Your Money Your Life) content standards. All information draws on regulatory prescribing information, peer-reviewed pharmacological and oncological literature, and established clinical guidelines. It does not replace professional medical advice, diagnosis, or treatment from a qualified oncologist, haematologist, physician, or specialist pharmacist. Cancer drug therapy decisions require individualised assessment by qualified oncology professionals with full knowledge of the patient’s diagnosis, staging, molecular profile, performance status, and concurrent medications. Self-diagnosis and self-treatment of cancer and serious medical conditions can be life-threatening. Always consult a qualified specialist before starting, changing, or stopping any cancer or specialty medication.